Iovance Biotherapeutics (IOVA) Net Income towards Common Stockholders (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Net Income towards Common Stockholders of -$79.0 million for Q1 2026, up 31.98% year-over-year from -$59.9 million in Q1 2025, and down 1027.24% quarter-over-quarter from $8.5 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$79.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 31.98% year-over-year to -$79.0 million; the TTM figure through Mar 2026 stood at -$273.4 million (up 27.16% YoY), while the FY2025 annual figure was -$310.5 million, up 16.58% from the prior year.
- Net Income towards Common Stockholders eased to -$79.0 million in Q1 2026 per IOVA's latest filing, from $8.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $8.5 million in Q4 2025 and bottomed at -$119.2 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$95.8 million across 5 years, with a median of -$105.3 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 52.98% — and 2025, when it surged 110.84%.
- Iovance Biotherapeutics' Net Income towards Common Stockholders stood at -$105.3 million in 2022, then decreased by 10.46% to -$116.3 million in 2023, then surged by 32.44% to -$78.6 million in 2024, then soared by 110.84% to $8.5 million in 2025, then slumped by 1027.24% to -$79.0 million in 2026.
- Business Quant data shows IOVA's Net Income towards Common Stockholders at -$79.0 million in Q1 2026, $8.5 million in Q4 2025, and -$91.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -47.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.29 Mn |
| Mar 31, 2026 | -79.01 Mn |
| Dec 31, 2025 | 8.52 Mn |
| Sep 30, 2025 | -91.25 Mn |
| Jun 30, 2025 | -111.67 Mn |
| Mar 31, 2025 | -116.16 Mn |
| Dec 31, 2024 | -78.60 Mn |
| Sep 30, 2024 | -83.56 Mn |
| Jun 30, 2024 | -97.06 Mn |
| Mar 31, 2024 | -112.98 Mn |
| Dec 31, 2023 | -116.34 Mn |
| Sep 30, 2023 | -113.76 Mn |
| Jun 30, 2023 | -106.53 Mn |
| Mar 31, 2023 | -107.37 Mn |
| Dec 31, 2022 | -105.32 Mn |
| Sep 30, 2022 | -99.62 Mn |
| Jun 30, 2022 | -99.35 Mn |
| Mar 31, 2022 | -119.19 Mn |
| Dec 31, 2021 | -93.09 Mn |
| Sep 30, 2021 | -89.73 Mn |